Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression
Open accessThe DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
Depression is a highly prevalent mood disorder and one of the major health concerns in modern society. Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Currently used antidepressant drugs, which mostly target brain monoaminergic neurotransmission, have limited clinical efficacy. Although the etiology of depression has not been fully elucidated, current scientific data emphasize the role of neurotrophic factors deficiencies, disturbed homeostasis between the nervous system and the immune and endocrine systems, as well as disturbances in brain energy metabolism and dysfunctions in the gut-brain axis as important factors in the pathogenesis of this neuropsychiatric disorder. Therefore, therapeutic options that could work in a way other than classic antidepressants are being sought to increase the effectiveness of the treatment. Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system. This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota. Graphic abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“At the same time, GLP-1 can also enhance the proliferation and differentiation of β cells and protect them from apoptosis [21].”
BackgroundZheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.44 · Cited by 2,023 · cited 1×
“Similar results were observed in an experiment involving a germ-free mouse strain, where the animals transplanted with microbiome isolated from depressed patients showed an increase in immobility time in the forced swim test and a decreased proportion of central motion distance in the open field test, compared to mice…”
ResultGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“GLP-1 exerts its biological effects by binding to a specific receptor (GLP-1R), which is expressed in different types of peripheral tissues and in the central nervous system [12].”
BackgroundThe microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846 · cited 1×
“The gut microbiota may influence the functioning of the host organism by modulating innate and adaptive immune responses [105].”
BackgroundKelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott, K., Moloney, G., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.019 · Cited by 1,683 · cited 2×
“People with depression are often characterized by a significantly lower number of microorganisms in the GI tract along with a decreased diversity of the gut microbiome [99].”
BackgroundWang, P. S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Borges, G., Bromet, E. J., Bruffaerts, R., de Girolamo, G., de Graaf, R., Gureje, O., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61414-7 · Cited by 1,655 · cited 1×
“76–85% of people living in low- or middle-income countries and suffering from this mental illness are not adequately treated [1].”
BackgroundNeuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073
Clinical and Biochemical Manifestations of Depression
Gold, P. W., Goodwin, F. K., & Chrousos, G. P. (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190706 · Cited by 1,053
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Furthermore, emerging data supports that glucagon-like peptide-1 (GLP-1) agonists, such as liraglutide, have pro-cognitive, neuroprotective, and antidepressant effects (32).”
BackgroundThe gut microbiome and mental health: advances in research and emerging priorities
Shoubridge, A. P., Choo, J. M., Martin, A. M., Keating, D. J., Wong, M., Licinio, J., & Rogers, G. B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01479-w · Cited by 144
“In addition to its role in regulating feeding behaviour [106], therapeutic targeting of GLP-1 signalling via GLP-1 receptors is now being considered in the context of mood disorders and neurodegenerative diseases (reviewed by Detka and Glombik [107]).”
BackgroundGlucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
GLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Tobaiqy, M., & Elkout, H. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01694-7 · Cited by 88
“Neuropsychiatric safety issues have become an area of interest given that many approved anti-obesity medications are centrally acting appetite suppressants [18, 19].”
Background
Metadata
- Authors
- Detka, J., & Głombik, K.
- Affiliations
- Maj Institute of Pharmacology (PL)
- Corresponding author
- Detka, Jan
- Venue
- Pharmacological Reports
- Published
- 2021-05-18
- Volume
- 73
- Issue
- 4
- Pages
- 1020-1032
- ISSN
- 1734-1140 (ISSN-L)
- 2299-5684
- PMC
- PMC8413152
- OpenAlex
- W3162613451
- Cited by
- 79
- References
- 130
- Citations by year
- 2026: 10 · 2025: 34 · 2024: 16 · 2023: 10 · 2022: 8 · 2021: 1
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Pharmacological Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Instytut Farmakologii, Polskiej Akademii Nauk (Statutory Funds)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, depression, antidepressant effects, neuroprotection, neuroinflammation, stress response, brain energy metabolism, gut-brain axis, gut microbiota, type 2 diabetes, obesity, neurotrophic factors
- MeSH terms
- Neuroprotection, Gastrointestinal Microbiome, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antidepressive Agents, Depression, Energy Metabolism, Humans, Inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. https://app.cochat.ai/papers/10.1007/s43440-021-00274-8
- The paper
- Detka, J., & Głombik, K. (2021). Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacological Reports. https://doi.org/10.1007/s43440-021-00274-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.